ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The company's shares are continuing on yesterday's gains…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday's meteoric rise. The digital health company provided another positive release to the ASX today.

At the time of writing, ResApp shares are fetching for 9.3 cents apiece, up 4.49%. It's worth noting that during early morning trade, its shares reached an intraday high of 10.2 cents.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

ResApp secures rebate on COVID-19 study

Investors are pushing ResApp shares higher after the company secured a cashback for its COVID-19 research program.

According to the release, ResApp advised it has received approval from AusIndustry for its application for an Advanced and Overseas Finding. In particular, this is in relation to the expenditure associated with its COVID-19 clinical studies.

The finding covers the financial years between 2021 to 2023, meaning that ResApp will be eligible for a cash rebate. This refers to the company's COVID-19 overseas research and development expenditure, thus receiving a 43.5% cashback from the Australian government.

As such, ResApp estimates that it will collect a rebate of around $820,000 for the financial year that ended 30 June 2021.

In the United States, the company is currently recruiting participants for its upcoming pilot study. The aim is to collect data to train an algorithm in identifying COVID-19 through cough sounds recorded on a smartphone.

The same participants will also be used in a second study to collect further cough sounds and data on disease progression. ResApp hopes to develop algorithms to remotely monitor patients with COVID-19.

ResApp CEO and managing director, Dr Tony Keating commented:

Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs.

We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.

ResApp share price summary

Until recently, ResApp shares were trading at multi-year lows, before shooting up in September. The past month alone has netted investors a return of more than 115%, however year-to-date, is up marginally at 14%.

ResApp commands a market capitalisation of about $83.3 million and has 859 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A girl sits on her bed in her room while using laptop and listening to headphones.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another rough ride for investors this Thursday.

Read more »

ETF written in yellow with a yellow underline and the full word spelt out in white underneath.
ASX Share Market News

5 amazing ASX ETFs for Australian investors in August

Looking for ETF ideas? Here are five to consider.

Read more »

Smiling woman with her head and arm on a desk holding $100 notes, symbolising dividends.
Broker Notes

For a yield of more than 7% and capital gains check out this ASX property trust: Broker

Could this company deliver the best of both worlds?

Read more »

An old-fashioned news boy stands on a stool and yells through a microphone in an open field.
ASX Share Market News

Why is everyone talking about Treasury Wine, ANZ and Telstra shares on Thursday?

Telstra, Treasury Wine, and ANZ shares are turning heads today. But why?

Read more »

An aircraft maintenance technician stands atop a platform inspecting the jets of an aircraft within a hangar.
Broker Notes

This ASX critical minerals producer could more than triple in value: Broker

This hi-tech company is growing its revenues fast.

Read more »

Stressed shopper holding shopping bags.
Broker Notes

Premier Investments shares will go how high? 2 brokers have their say

Are these shares looking like a bargain?

Read more »

A boy is about to rocket from a copper-coloured field of hay into the sky.
ASX Share Market News

3 ASX 200 shares tipped to grow 45% to 75% over the next 12 months

These ASX 200 shares are trading for cheap right now.

Read more »

Stressed man in an an office with his eyes closed and phone in his hand, with investing graphs open on two iMacs.
Broker Notes

Why Bell Potter just downgraded this popular ASX 200 stock

The broker is feeling cautious about this fallen giant.

Read more »